Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Nuvalent's Q2 results essentially in-line, says Piper Sandler » 12:01
09/08/21
09/08
12:01
09/08/21
12:01
NUVL

Nuvalent

$38.30 /

-0.53 (-1.36%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond retains an Overweight rating on Nuvalent after the company's Q2 results came in essentially in-line with estimates, and says he likes the setup for shares. Next-generation ROS1 inhibitor NUVL-520 will enter the clinic in 2H21, allowing for a first look at clinical data by year-end 2022, with next-generation ALK inhibitor NVL-655 ~6mos behind and expected to enter the clinic in 1H22, Raymond tells investors in a research note.

ShowHide Related Items >><<
NUVL Nuvalent
$38.30 /

-0.53 (-1.36%)

08/23/21 Cowen
Nuvalent initiated with an Outperform on tumor 'potency' at Cowen
08/23/21 JPMorgan
Nuvalent initiated with an Overweight, $34 target at JPMorgan
08/23/21 JPMorgan
Nuvalent initiated with an Overweight at JPMorgan
08/23/21 Cowen
Nuvalent initiated with an Outperform at Cowen
NUVL Nuvalent
$38.30 /

-0.53 (-1.36%)

  • 29
    Jul
NUVL Nuvalent
$38.30 /

-0.53 (-1.36%)

Earnings
Nuvalent reports Q2 EPS ($3.17), two estimates (19c) » 06:35
09/08/21
09/08
06:35
09/08/21
06:35
NUVL

Nuvalent

$38.75 /

+0.555 (+1.45%)

"At Nuvalent, we are…

"At Nuvalent, we are leveraging our team's deep expertise in chemistry and structure-based drug design to advance a novel pipeline of product candidates for patients with cancer. Our therapies are specifically designed to solve for challenges limiting the activity and durability of currently available therapies, such as kinase resistance, adverse events due to off-target activity, and metastases to the brain," said James Porter, Ph.D., Chief Executive Officer at Nuvalent. "In the first half of 2021, our team has made meaningful progress to deliver on our clear vision for advancing the field of precision oncology. We have received clearance from the FDA to proceed with the Phase 1/2 study for our ROS1-selective inhibitor NVL-520, advanced our parallel lead product candidate, the ALK-selective inhibitor NVL-655, into IND-enabling studies, and progressed multiple additional discovery-stage research programs. With the recent talented additions to our team and capital raised in our upsized IPO, we stand well positioned to fuel our upcoming transition to a clinical organization and efforts to renew hope for patients in need."

ShowHide Related Items >><<
NUVL Nuvalent
$38.75 /

+0.555 (+1.45%)

08/23/21 Cowen
Nuvalent initiated with an Outperform on tumor 'potency' at Cowen
08/23/21 JPMorgan
Nuvalent initiated with an Overweight, $34 target at JPMorgan
08/23/21 JPMorgan
Nuvalent initiated with an Overweight at JPMorgan
08/23/21 Cowen
Nuvalent initiated with an Outperform at Cowen
  • 29
    Jul
NUVL Nuvalent
$38.75 /

+0.555 (+1.45%)

Over a month ago
Initiation
Nuvalent initiated with an Outperform on tumor 'potency' at Cowen » 08:17
08/23/21
08/23
08:17
08/23/21
08:17
NUVL

Nuvalent

$27.21 /

+0.44 (+1.64%)

Cowen analyst Marc Frahm…

Cowen analyst Marc Frahm initiated coverage of Nuvalent with an Outperform rating and no price target. The company's lead assets NVL-520 and NVL-655 have demonstrated "superior potency" against ROS1/ALK driven tumors, Frahm tells investors in a research note. He anticipates the agents are each capable of generating $800M-plus in sales.

ShowHide Related Items >><<
NUVL Nuvalent
$27.21 /

+0.44 (+1.64%)

08/23/21 JPMorgan
Nuvalent initiated with an Overweight, $34 target at JPMorgan
08/23/21 JPMorgan
Nuvalent initiated with an Overweight at JPMorgan
08/23/21 Cowen
Nuvalent initiated with an Outperform at Cowen
08/23/21 Piper Sandler
Nuvalent initiated with an Overweight at Piper Sandler
  • 29
    Jul
NUVL Nuvalent
$27.21 /

+0.44 (+1.64%)

Initiation
Nuvalent initiated with an Overweight, $34 target at JPMorgan » 07:52
08/23/21
08/23
07:52
08/23/21
07:52
NUVL

Nuvalent

$27.21 /

+0.44 (+1.64%)

JPMorgan analyst Anupam…

JPMorgan analyst Anupam Rama initiated coverage of Nuvalent with an Overweight rating and $34 price target. The analyst believes Nuvalent is taking an "interesting approach" to overcome key limitations for select kinases in established markets, by focusing on selectivity and resistance via chemistry- and structure-based drug design. He sees NVL-520 and NVL-655 as having best-in-class potential in their respective classes long term,

ShowHide Related Items >><<
NUVL Nuvalent
$27.21 /

+0.44 (+1.64%)

08/23/21 JPMorgan
Nuvalent initiated with an Overweight at JPMorgan
08/23/21 Cowen
Nuvalent initiated with an Outperform at Cowen
08/23/21 Piper Sandler
Nuvalent initiated with an Overweight at Piper Sandler
  • 29
    Jul
NUVL Nuvalent
$27.21 /

+0.44 (+1.64%)

Initiation
Nuvalent initiated with an Overweight at JPMorgan » 06:13
08/23/21
08/23
06:13
08/23/21
06:13
NUVL

Nuvalent

$27.21 /

+0.44 (+1.64%)

JPMorgan analyst Anupam…

JPMorgan analyst Anupam Rama initiated coverage of Nuvalent with an Overweight rating and $34 price target.

ShowHide Related Items >><<
NUVL Nuvalent
$27.21 /

+0.44 (+1.64%)

08/23/21 Cowen
Nuvalent initiated with an Outperform at Cowen
08/23/21 Piper Sandler
Nuvalent initiated with an Overweight at Piper Sandler
  • 29
    Jul
NUVL Nuvalent
$27.21 /

+0.44 (+1.64%)

Initiation
Nuvalent initiated with an Outperform at Cowen » 06:13
08/23/21
08/23
06:13
08/23/21
06:13
NUVL

Nuvalent

$27.21 /

+0.44 (+1.64%)

Cowen analyst Marc Frahm…

Cowen analyst Marc Frahm initiated coverage of Nuvalent with an Outperform rating.

ShowHide Related Items >><<
NUVL Nuvalent
$27.21 /

+0.44 (+1.64%)

08/23/21 Piper Sandler
Nuvalent initiated with an Overweight at Piper Sandler
  • 29
    Jul
NUVL Nuvalent
$27.21 /

+0.44 (+1.64%)

Initiation
Nuvalent initiated with an Overweight at Piper Sandler » 04:41
08/23/21
08/23
04:41
08/23/21
04:41
NUVL

Nuvalent

$27.21 /

+0.44 (+1.64%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond initiated coverage of Nuvalent with an Overweight rating and $40 price target. The analyst says the company's two lead assets - ROS1 inhibitor NVL-520 and ALK inhibitor NVL-655 - are "potentially best-in-class compounds." Extensive preclinical data is predictive of clinical superiority over both approved and known developmental agents, Raymond tells investors in a research note. The analyst views Nuvalent as an "essential biotech holding for intermediate/longer term investors."

ShowHide Related Items >><<
  • 29
    Jul
NUVL Nuvalent
$27.21 /

+0.44 (+1.64%)

On The Fly
Opening Day: Sportradar files for IPO after SPAC talks break off » 08:27
08/21/21
08/21
08:27
08/21/21
08:27
ARBK

Argo Blockchain

/

+

, ARBKF

Argo Blockchain

$1.83 /

+0.15 (+8.93%)

, PRCT

Procept BioRobotics

/

+

, SRAD

Sportradar

/

+

, QNIU

Qiniu

/

+

, CMSL

Camposol

/

+

, SPRK

Spark Education

/

+

, SCAN

Perspectum Group

/

+

, AUTH

Authentic Brands Group

$8.01 /

+ (+0.00%)

, BLK

BlackRock

$917.42 /

+14.44 (+1.60%)

, SPG

Simon Property

$128.78 /

+0.35 (+0.27%)

, MS

Morgan Stanley

$100.71 /

+1.01 (+1.01%)

, GS

Goldman Sachs

$396.03 /

+2.76 (+0.70%)

, BCS

Barclays

$9.96 /

+0.01 (+0.10%)

, BAC

Bank of America

$40.38 /

+0.195 (+0.49%)

, MXCT

MaxCyte

$14.39 /

+0.61 (+4.43%)

, RXST

RxSight

$11.89 /

-0.175 (-1.45%)

, TNYA

Tenaya Therapeutics

$22.31 /

+1.41 (+6.75%)

, RANI

Rani Therapeutics

$16.11 /

-0.93 (-5.46%)

, NUVL

Nuvalent

$27.21 /

+0.44 (+1.64%)

, ICVX

Icosavax

$34.69 /

+0.69 (+2.03%)

, RSKD

Riskified

$28.61 /

+1.445 (+5.32%)

, OMGA

Omega Therapeutics

$21.94 /

-0.09 (-0.41%)

, IMRX

Immuneering

$30.23 /

-0.53 (-1.72%)

, INAB

In8bio

$7.64 /

-0.22 (-2.80%)

, HOOD

Robinhood

$42.62 /

-1.99 (-4.46%)

, RLYB

Rallybio

$12.57 /

-0.23 (-1.80%)

, ABVC

ABVC BioPharma

$2.03 /

-0.12 (-5.58%)

In a quiet week for IPOs,…

ShowHide Related Items >><<
SPG Simon Property
$128.78 /

+0.35 (+0.27%)

RLYB Rallybio
$12.57 /

-0.23 (-1.80%)

MXCT MaxCyte
$14.39 /

+0.61 (+4.43%)

MS Morgan Stanley
$100.71 /

+1.01 (+1.01%)

INAB In8bio
$7.64 /

-0.22 (-2.80%)

ICVX Icosavax
$34.69 /

+0.69 (+2.03%)

HOOD Robinhood
$42.62 /

-1.99 (-4.46%)

GS Goldman Sachs
$396.03 /

+2.76 (+0.70%)

BLK BlackRock
$917.42 /

+14.44 (+1.60%)

BCS Barclays
$9.96 /

+0.01 (+0.10%)

BAC Bank of America
$40.38 /

+0.195 (+0.49%)

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

ARBK Argo Blockchain
/

+

ARBKF Argo Blockchain
$1.83 /

+0.15 (+8.93%)

06/01/21 H.C. Wainwright
Argo Blockchain initiated with a Buy at H.C. Wainwright
PRCT Procept BioRobotics
/

+

SRAD Sportradar
/

+

QNIU Qiniu
/

+

CMSL Camposol
/

+

SPRK Spark Education
/

+

SCAN Perspectum Group
/

+

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

BLK BlackRock
$917.42 /

+14.44 (+1.60%)

07/15/21 Credit Suisse
BlackRock price target lowered to $1,000 from $1,011 at Credit Suisse
07/15/21 Argus
BlackRock price target raised to $975 from $950 at Argus
07/15/21 Deutsche Bank
BlackRock price target lowered to $1,001 from $1,018 at Deutsche Bank
07/15/21 BMO Capital
BlackRock price target raised to $803 from $773 at BMO Capital
SPG Simon Property
$128.78 /

+0.35 (+0.27%)

08/16/21 Truist
Simon Property price target raised to $136 from $130 at Truist
08/13/21 Truist
Simon Property price target raised to $136 from $130 at Truist
08/13/21 Morgan Stanley
Simon Property price target raised to $161 from $150 at Morgan Stanley
08/04/21 BofA
Simon Property upgraded to Buy from Neutral at BofA
MS Morgan Stanley
$100.71 /

+1.01 (+1.01%)

08/13/21 Seaport Global
Morgan Stanley downgraded to Neutral at Seaport Global on valuation
08/13/21 Seaport Global
Morgan Stanley downgraded to Neutral from Buy at Seaport Global
07/19/21 Citi
Morgan Stanley price target raised to $97 from $88 at Citi
07/16/21 Argus
Morgan Stanley price target raised to $105 from $93 at Argus
GS Goldman Sachs
$396.03 /

+2.76 (+0.70%)

07/14/21 Oppenheimer
Goldman Sachs price target raised to $540 from $493 at Oppenheimer
07/14/21 Credit Suisse
Goldman Sachs price target raised to $425 from $420 at Credit Suisse
07/14/21 Mizuho
Affirm selloff on Apple competition fears overblown, says Mizuho
07/14/21 Piper Sandler
Goldman Sachs price target raised to $435 from $420 at Piper Sandler
BCS Barclays
$9.96 /

+0.01 (+0.10%)

08/02/21 RBC Capital
Barclays price target raised to 190 GBp from 180 GBp at RBC Capital
07/30/21 Morgan Stanley
Barclays price target raised to 205 GBp from 200 GBp at Morgan Stanley
07/29/21 UBS
Barclays price target raised to 220 GBp from 210 GBp at UBS
07/29/21 Deutsche Bank
Barclays price target raised to 240 GBp from 230 GBp at Deutsche Bank
BAC Bank of America
$40.38 /

+0.195 (+0.49%)

07/19/21 Odeon Capital
Bank of America downgraded to Hold from Buy at Odeon Capital
07/06/21 Keefe Bruyette
Bank of America assumed with a Market Perform at Keefe Bruyette
06/02/21 Truist
Bank of America initiated with a Buy at Truist
05/04/21
Fly Intel: Top five analyst downgrades
MXCT MaxCyte
$14.39 /

+0.61 (+4.43%)

RXST RxSight
$11.89 /

-0.175 (-1.45%)

TNYA Tenaya Therapeutics
$22.31 /

+1.41 (+6.75%)

RANI Rani Therapeutics
$16.11 /

-0.93 (-5.46%)

NUVL Nuvalent
$27.21 /

+0.44 (+1.64%)

ICVX Icosavax
$34.69 /

+0.69 (+2.03%)

RSKD Riskified
$28.61 /

+1.445 (+5.32%)

OMGA Omega Therapeutics
$21.94 /

-0.09 (-0.41%)

IMRX Immuneering
$30.23 /

-0.53 (-1.72%)

INAB In8bio
$7.64 /

-0.22 (-2.80%)

HOOD Robinhood
$42.62 /

-1.99 (-4.46%)

08/17/21 Redburn
Redburn starts Robinhood at Buy with fair value implying 29% upside
08/17/21 Redburn
Robinhood initiated with a Buy at Redburn
08/05/21 Wolfe Research
Robinhood initiated with a Peer Perform at Wolfe Research
07/29/21
Fly Intel: Top five analyst initiations
RLYB Rallybio
$12.57 /

-0.23 (-1.80%)

ABVC ABVC BioPharma
$2.03 /

-0.12 (-5.58%)

SPG Simon Property
$128.78 /

+0.35 (+0.27%)

MS Morgan Stanley
$100.71 /

+1.01 (+1.01%)

HOOD Robinhood
$42.62 /

-1.99 (-4.46%)

GS Goldman Sachs
$396.03 /

+2.76 (+0.70%)

BLK BlackRock
$917.42 /

+14.44 (+1.60%)

BCS Barclays
$9.96 /

+0.01 (+0.10%)

BAC Bank of America
$40.38 /

+0.195 (+0.49%)

ABVC ABVC BioPharma
$2.03 /

-0.12 (-5.58%)

  • 30
    Jul
  • 30
    Jul
  • 30
    Jul
  • 30
    Jul
  • 29
    Jul
  • 30
    Jul
  • 30
    Jul
  • 29
    Jul
  • 30
    Jul
  • 29
    Jul
  • 29
    Jul
  • 29
    Jul
  • 16
    Jul
  • 19
    Nov
  • 13
    Nov
SRAD Sportradar
/

+

MS Morgan Stanley
$100.71 /

+1.01 (+1.01%)

HOOD Robinhood
$42.62 /

-1.99 (-4.46%)

GS Goldman Sachs
$396.03 /

+2.76 (+0.70%)

BLK BlackRock
$917.42 /

+14.44 (+1.60%)

BCS Barclays
$9.96 /

+0.01 (+0.10%)

BAC Bank of America
$40.38 /

+0.195 (+0.49%)

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

SRAD Sportradar
/

+

SPG Simon Property
$128.78 /

+0.35 (+0.27%)

RXST RxSight
$11.89 /

-0.175 (-1.45%)

QNIU Qiniu
/

+

HOOD Robinhood
$42.62 /

-1.99 (-4.46%)

GS Goldman Sachs
$396.03 /

+2.76 (+0.70%)

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

SPG Simon Property
$128.78 /

+0.35 (+0.27%)

MS Morgan Stanley
$100.71 /

+1.01 (+1.01%)

HOOD Robinhood
$42.62 /

-1.99 (-4.46%)

GS Goldman Sachs
$396.03 /

+2.76 (+0.70%)

BAC Bank of America
$40.38 /

+0.195 (+0.49%)

On The Fly
Opening Day: Robinhood shares fall after IPO » 08:53
07/31/21
07/31
08:53
07/31/21
08:53
MXCT

MaxCyte

$16.89 /

-0.11 (-0.65%)

, RXST

RxSight

$16.42 /

-1.33 (-7.49%)

, TNYA

Tenaya Therapeutics

$15.75 /

-3.94 (-20.01%)

, RANI

Rani Therapeutics

$10.95 /

-0.37 (-3.27%)

, OMGA

Omega Therapeutics

$16.05 /

-4.43 (-21.63%)

, IMRX

Immuneering

$17.72 /

-1.94 (-9.87%)

, INAB

In8bio

$10.01 /

-0.13 (-1.28%)

, DOLE

Dole

$14.55 /

-0.65 (-4.28%)

, HOOD

Robinhood

$35.57 /

+0.75 (+2.15%)

, NUVL

Nuvalent

$18.42 /

-0.39 (-2.07%)

, ICVX

Icosavax

$25.00 /

-8.68 (-25.77%)

, RSKD

Riskified

$27.18 /

+0.99 (+3.78%)

, COOK

Traeger

$22.21 /

+0.2 (+0.91%)

, RLYB

Rallybio

$17.42 /

+3.02 (+20.97%)

, DUOL

Duolingo

$140.08 /

+3.13 (+2.29%)

, MLNK

MeridianLink

$23.90 /

-0.63 (-2.57%)

, PWSC

PowerSchool

$18.49 /

+0.02 (+0.11%)

, CADL

Candel Therapeutics

$7.63 /

+0.06 (+0.79%)

, SNTG

Sentage

$5.36 /

+0.55 (+11.43%)

, RNAZ

Transcode Therapeutics

$2.96 /

+0.035 (+1.20%)

, AGRI

AgriFORCE Growing Systems

$3.42 /

+0.32 (+10.32%)

, MITQ

Moving iMage

$3.89 /

-0.1 (-2.51%)

, IINN

Inspira Technologies

$3.88 /

-0.05 (-1.27%)

, UNCY

Unicycive Therapeutics

$2.76 /

-0.05 (-1.78%)

, SPRK

Spark Education

/

+

, QNIU

Qiniu

/

+

, CMSL

Camposol

/

+

, SCAN

Perspectum Group

/

+

, AUTH

Authentic Brands Group

$8.01 /

+ (+0.00%)

, MS

Morgan Stanley

$95.97 /

-0.295 (-0.31%)

, GS

Goldman Sachs

$375.04 /

-2.43 (-0.64%)

, BCS

Barclays

$9.78 /

-0.18 (-1.81%)

, BAC

Bank of America

$38.35 /

-0.335 (-0.87%)

, BLK

BlackRock

$867.23 /

-1.6 (-0.18%)

, SPG

Simon Property

$126.52 /

+0.63 (+0.50%)

Shares of Robinhood…

ShowHide Related Items >><<
SPG Simon Property
$126.52 /

+0.63 (+0.50%)

RLYB Rallybio
$17.42 /

+3.02 (+20.97%)

MS Morgan Stanley
$95.97 /

-0.295 (-0.31%)

MITQ Moving iMage
$3.89 /

-0.1 (-2.51%)

HOOD Robinhood
$35.57 /

+0.75 (+2.15%)

GS Goldman Sachs
$375.04 /

-2.43 (-0.64%)

BLK BlackRock
$867.23 /

-1.6 (-0.18%)

BCS Barclays
$9.78 /

-0.18 (-1.81%)

BAC Bank of America
$38.35 /

-0.335 (-0.87%)

AGRI AgriFORCE Growing Systems
$3.42 /

+0.32 (+10.32%)

MXCT MaxCyte
$16.89 /

-0.11 (-0.65%)

RXST RxSight
$16.42 /

-1.33 (-7.49%)

TNYA Tenaya Therapeutics
$15.75 /

-3.94 (-20.01%)

RANI Rani Therapeutics
$10.95 /

-0.37 (-3.27%)

OMGA Omega Therapeutics
$16.05 /

-4.43 (-21.63%)

IMRX Immuneering
$17.72 /

-1.94 (-9.87%)

INAB In8bio
$10.01 /

-0.13 (-1.28%)

DOLE Dole
$14.55 /

-0.65 (-4.28%)

HOOD Robinhood
$35.57 /

+0.75 (+2.15%)

07/29/21
Fly Intel: Top five analyst initiations
07/29/21 Atlantic Equities
Robinhood initiated with an Overweight at Atlantic Equities
NUVL Nuvalent
$18.42 /

-0.39 (-2.07%)

ICVX Icosavax
$25.00 /

-8.68 (-25.77%)

RSKD Riskified
$27.18 /

+0.99 (+3.78%)

COOK Traeger
$22.21 /

+0.2 (+0.91%)

RLYB Rallybio
$17.42 /

+3.02 (+20.97%)

DUOL Duolingo
$140.08 /

+3.13 (+2.29%)

MLNK MeridianLink
$23.90 /

-0.63 (-2.57%)

PWSC PowerSchool
$18.49 /

+0.02 (+0.11%)

CADL Candel Therapeutics
$7.63 /

+0.06 (+0.79%)

SNTG Sentage
$5.36 /

+0.55 (+11.43%)

RNAZ Transcode Therapeutics
$2.96 /

+0.035 (+1.20%)

AGRI AgriFORCE Growing Systems
$3.42 /

+0.32 (+10.32%)

MITQ Moving iMage
$3.89 /

-0.1 (-2.51%)

IINN Inspira Technologies
$3.88 /

-0.05 (-1.27%)

UNCY Unicycive Therapeutics
$2.76 /

-0.05 (-1.78%)

SPRK Spark Education
/

+

QNIU Qiniu
/

+

CMSL Camposol
/

+

SCAN Perspectum Group
/

+

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

MS Morgan Stanley
$95.97 /

-0.295 (-0.31%)

07/19/21 Citi
Morgan Stanley price target raised to $97 from $88 at Citi
07/16/21 Argus
Morgan Stanley price target raised to $105 from $93 at Argus
07/16/21 BMO Capital
Morgan Stanley price target raised to $103 from $97 at BMO Capital
07/16/21 Piper Sandler
Morgan Stanley price target raised to $100 from $93 at Piper Sandler
GS Goldman Sachs
$375.04 /

-2.43 (-0.64%)

07/14/21 Oppenheimer
Goldman Sachs price target raised to $540 from $493 at Oppenheimer
07/14/21 Credit Suisse
Goldman Sachs price target raised to $425 from $420 at Credit Suisse
07/14/21 Mizuho
Affirm selloff on Apple competition fears overblown, says Mizuho
07/14/21 Piper Sandler
Goldman Sachs price target raised to $435 from $420 at Piper Sandler
BCS Barclays
$9.78 /

-0.18 (-1.81%)

07/30/21 Morgan Stanley
Barclays price target raised to 205 GBp from 200 GBp at Morgan Stanley
07/29/21 UBS
Barclays price target raised to 220 GBp from 210 GBp at UBS
07/29/21 Deutsche Bank
Barclays price target raised to 240 GBp from 230 GBp at Deutsche Bank
07/29/21 Societe Generale
Barclays price target raised to 180 GBp from 170 GBp at Societe Generale
BAC Bank of America
$38.35 /

-0.335 (-0.87%)

07/19/21 Odeon Capital
Bank of America downgraded to Hold from Buy at Odeon Capital
07/06/21 Keefe Bruyette
Bank of America assumed with a Market Perform at Keefe Bruyette
06/02/21 Truist
Bank of America initiated with a Buy at Truist
05/04/21
Fly Intel: Top five analyst downgrades
BLK BlackRock
$867.23 /

-1.6 (-0.18%)

07/15/21 Credit Suisse
BlackRock price target lowered to $1,000 from $1,011 at Credit Suisse
07/15/21 Argus
BlackRock price target raised to $975 from $950 at Argus
07/15/21 Deutsche Bank
BlackRock price target lowered to $1,001 from $1,018 at Deutsche Bank
07/15/21 BMO Capital
BlackRock price target raised to $803 from $773 at BMO Capital
SPG Simon Property
$126.52 /

+0.63 (+0.50%)

07/19/21 Stifel
Simon Property upgraded to Buy from Hold at Stifel
06/28/21 Scotiabank
Simon Property price target raised to $138 from $117 at Scotiabank
06/22/21 Truist
Simon Property price target raised to $130 from $102 at Truist
06/21/21 Stifel
Simon Property price target raised to $125 from $120 at Stifel
SPG Simon Property
$126.52 /

+0.63 (+0.50%)

MS Morgan Stanley
$95.97 /

-0.295 (-0.31%)

GS Goldman Sachs
$375.04 /

-2.43 (-0.64%)

BLK BlackRock
$867.23 /

-1.6 (-0.18%)

BCS Barclays
$9.78 /

-0.18 (-1.81%)

BAC Bank of America
$38.35 /

-0.335 (-0.87%)

  • 30
    Jul
  • 30
    Jul
  • 30
    Jul
  • 30
    Jul
  • 29
    Jul
  • 30
    Jul
  • 30
    Jul
  • 29
    Jul
  • 30
    Jul
  • 29
    Jul
  • 29
    Jul
  • 28
    Jul
  • 28
    Jul
  • 30
    Jul
  • 28
    Jul
  • 29
    Jul
  • 29
    Jul
  • 27
    Jul
  • 14
    Jul
  • 16
    Jul
  • 08
    Jul
  • 08
    Jul
  • 08
    Jul
  • 19
    Nov
  • 13
    Nov
MS Morgan Stanley
$95.97 /

-0.295 (-0.31%)

HOOD Robinhood
$35.57 /

+0.75 (+2.15%)

GS Goldman Sachs
$375.04 /

-2.43 (-0.64%)

DUOL Duolingo
$140.08 /

+3.13 (+2.29%)

DOLE Dole
$14.55 /

-0.65 (-4.28%)

BLK BlackRock
$867.23 /

-1.6 (-0.18%)

BCS Barclays
$9.78 /

-0.18 (-1.81%)

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

SPRK Spark Education
/

+

SPG Simon Property
$126.52 /

+0.63 (+0.50%)

RXST RxSight
$16.42 /

-1.33 (-7.49%)

MS Morgan Stanley
$95.97 /

-0.295 (-0.31%)

HOOD Robinhood
$35.57 /

+0.75 (+2.15%)

GS Goldman Sachs
$375.04 /

-2.43 (-0.64%)

DUOL Duolingo
$140.08 /

+3.13 (+2.29%)

BLK BlackRock
$867.23 /

-1.6 (-0.18%)

BCS Barclays
$9.78 /

-0.18 (-1.81%)

BAC Bank of America
$38.35 /

-0.335 (-0.87%)

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

SPG Simon Property
$126.52 /

+0.63 (+0.50%)

MS Morgan Stanley
$95.97 /

-0.295 (-0.31%)

GS Goldman Sachs
$375.04 /

-2.43 (-0.64%)

BAC Bank of America
$38.35 /

-0.335 (-0.87%)

Syndicate
Nuvalent opens at $18.10, IPO priced at $17 per share » 12:24
07/29/21
07/29
12:24
07/29/21
12:24
NUVL

Nuvalent

/

+

Nuvalent, which said it…

Nuvalent, which said it is "creating precisely targeted therapies designed to overcome the limitations of existing therapies for clinically proven kinase targets for patients with cancer," has parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs.

ShowHide Related Items >><<
  • 29
    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.